Pharmacological targeting of glucagon and glucagon-like peptide 1 receptors has different effects on energy state and glucose homeostasis in diet-induced obese mice

Journal of Pharmacology and Experimental Therapeutics

Volumn 338, Issue 1, 2011, Pages 70-81

  Gu, Wei ^a   Lloyd, David J ^a   Chinookswong, Narumol ^a   Komorowski, Renée ^a   Sivits Jr , Glenn ^a   Graham, Melissa ^a   Winters, Katherine A ^a   Yan, Hai ^a   Boros, Laszlo G ^b   Lindberg, Richard A ^a   Véniant, Murielle M ^a  

^a AMGEN INC   (United States)

^b SIDMAP LLC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCAGON; GLUCAGON LIKE PEPTIDE 1 [23]; GLUCAGON LIKE PEPTIDE 1 DERIVATIVE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; GLUCAGON RECEPTOR ANTIBODY; GLUCOSE; RECEPTOR ANTIBODY; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; BROWN ADIPOSE TISSUE; CONTROLLED STUDY; DRUG EFFECT; DRUG TARGETING; FOOD INTAKE; GENE EXPRESSION; GLUCOSE CLAMP TECHNIQUE; GLUCOSE HOMEOSTASIS; GLUCOSE METABOLISM; GLUCOSE TOLERANCE TEST; GLUCOSE TRANSPORT; GLYCOGEN SYNTHESIS; GLYCOLYSIS; KIDNEY; LIPID METABOLISM; LIVER; MALE; METABOLIC RATE; MOUSE; MUSCLE; NONHUMAN; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RESPIRATORY QUOTIENT; WEIGHT REDUCTION;

ANIMALS; ANTIBODIES, MONOCLONAL; BLOOD GLUCOSE; BODY WEIGHT; DIETARY FATS; DRUG DELIVERY SYSTEMS; ENERGY METABOLISM; GLUCAGON-LIKE PEPTIDE 1; HOMEOSTASIS; HUMANS; MALE; MICE; MICE, INBRED C57BL; OBESITY; RECEPTORS, GLUCAGON;

EID: 79959525534     PISSN: 00223565     EISSN: 15210103     Source Type: Journal    
DOI: 10.1124/jpet.111.179986     Document Type: Article

References (38)

1. Boros LG, Cascante M, and Lee WN (2002) Metabolic profiling of cell growth and death in cancer: applications in drug discovery. Drug Discov Today 7:364-372. (Pubitemid 34226656)
2. Bulotta A, Perfetti R, Hui H, and Boros LG (2003) GLP-1 stimulates glucose-derived de novo fatty acid synthesis and chain elongation during cell differentiation and insulin release. J Lipid Res 44:1559-1565. (Pubitemid 37279601)
3. Day JW, Ottaway N, Patterson JT, Gelfanov V, Smiley D, Gidda J, Findeisen H, Bruemmer D, Drucker DJ, Chaudhary N, et al. (2009) A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat Chem Biol 5:749-757.
4. Drucker DJ and Nauck MA (2006) The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 368:1696-1705. (Pubitemid 46048557)
5. Drucker DJ, Philippe J, Mojsov S, Chick WL, and Habener JF (1987) Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proc Natl Acad Sci USA 84:3434-3438. (Pubitemid 17085418)
6. Duez H, Smith AC, Xiao C, Giacca A, Szeto L, Drucker DJ, and Lewis GF (2009) Acute dipeptidyl peptidase-4 inhibition rapidly enhances insulin-mediated suppression of endogenous glucose production in mice. Endocrinology 150:56-62.
7. Egan JM, Montrose-Rafizadeh C, Wang Y, Bernier M, and Roth J (1994) Glucagonlike peptide-1(7-36) amide (GLP-1) enhances insulin-stimulated glucose metabolism in 3T3-L1 adipocytes: one of several potential extrapancreatic sites of GLP-1 action. Endocrinology 135:2070-2075. (Pubitemid 24363904)
8. Ferré P, Burnol AF, Leturque A, Terretaz J, Penicaud L, Jeanrenaud B, and Girard J (1986) Glucose utilization in vivo and insulin-sensitivity of rat brown adipose tissue in various physiological and pathological conditions. Biochem J 233:249-252. (Pubitemid 16063799)
9. Flint A, Raben A, Astrup A, and Holst JJ (1998) Glucagon-like peptide 1 promotes satiety and suppresses energy intake in humans. J Clin Invest 101:515-520. (Pubitemid 28084232)
10. Greig NH, Holloway HW, De Ore KA, Jani D, Wang Y, Zhou J, Garant MJ, and Egan JM (1999) Once daily injection of exendin-4 to diabetic mice achieves long-term beneficial effects on blood glucose concentrations. Diabetologia 42:45-50. (Pubitemid 29039736)
11. Gu W, Winters KA, Motani AS, Komorowski R, Zhang Y, Liu Q, Wu X, Rulifson IC, Sivits G Jr, Graham M, et al. (2010) Glucagon receptor antagonist-mediated improvements in glycemic control are dependent on functional pancreatic GLP-1 receptor. Am J Physiol Endocrinol Metab 299:E624-E632.
12. Gu W, Yan H, Winters KA, Komorowski R, Vonderfecht S, Atangan L, Sivits G, Hill D, Yang J, Bi V, et al. (2009) Long-term inhibition of the glucagon receptor with a monoclonal antibody in mice causes sustained improvement in glycemic control, with reversible α-cell hyperplasia and hyperglucagonemia. J Pharmacol Exp Ther 331:871-881.
13. Holness MJ, Liu YL, Beech JS, and Sugden MC (1991) Glucose utilization by interscapular brown adipose tissue in vivo during nutritional transitions in the rat. Biochem J 273:233-235.
14. Jiang G and Zhang BB (2003) Glucagon and regulation of glucose metabolism. Am J Physiol Endocrinol Metab 284:E671-E678. (Pubitemid 36323859)
15. Klain GJ (1977) In vivo effects of glucagon on fatty acid synthesis in fasted and refed rats. J Nutr 107:942-948.
16. Knauf C, Cani PD, Perrin C, Iglesias MA, Maury JF, Bernard E, Benhamed F, Grémeaux T, Drucker DJ, Kahn CR, et al. (2005) Brain glucagon-like peptide-1 increases insulin secretion and muscle insulin resistance to favor hepatic glycogen storage. J Clin Invest 115:3554-3563. (Pubitemid 43121843)
17. Lee WN, Boros LG, Puigjaner J, Bassilian S, Lim S, and Cascante M (1998) Mass isotopomer study of the nonoxidative pathways of the pentose cycle with [1,2-13C2]glucose. Am J Physiol Endocrinol Metab 274:E843-E851.
18. Lee WN, Byerley LO, Bassilian S, Ajie HO, Clark I, Edmond J, and Bergner EA (1995) Isotopomer study of lipogenesis in human hepatoma cells in culture: contribution of carbon and hydrogen atoms from glucose. Anal Biochem 226:100-112.
19. Lee WN, Edmond J, Bassilian S, and Morrow JW (1996) Mass isotopomer study of glutamine oxidation and synthesis in primary culture of astrocytes. Dev Neurosci 18:469-477.
20. Leimer KR, Rice RH, and Gehrke CW (1977) Complete mass spectra of N-trifluoroacetyl-n-butyl esters of amino acids. J Chromatogr 141:121-144.
21. Liang Y, Osborne MC, Monia BP, Bhanot S, Gaarde WA, Reed C, She P, Jetton TL, and Demarest KT (2004) Reduction in glucagon receptor expression by an antisense oligonucleotide ameliorates diabetic syndrome in db/db mice. Diabetes 53: 410-417. (Pubitemid 38174557)
22. Meeran K, O'Shea D, Edwards CM, Turton MD, Heath MM, Gunn I, Abusnana S, Rossi M, Small CJ, Goldstone AP, et al. (1999) Repeated intracerebroventricular administration of glucagon-like peptide-1-(7-36) amide or exendin-(9-39) alters body weight in the rat. Endocrinology 140:244-250. (Pubitemid 29011165)
23. Miranda LP, Winters KA, Gegg CV, Patel A, Aral J, Long J, Zhang J, Diamond S, Guido M, Stanislaus S, et al. (2008) Design and synthesis of conformationally constrained glucagon-like peptide-1 derivatives with increased plasma stability and prolonged in vivo activity. J Med Chem 51:2758-2765. (Pubitemid 351620797)
24. Näslund E, Barkeling B, King N, Gutniak M, Blundell JE, Holst JJ, Rössner S, and Hellström PM (1999) Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. Int J Obes Relat Metab Disord 23:304-311.
25. Nauck MA, Niedereichholz U, Ettler R, Holst JJ, Orskov C, Ritzel R, and Schmiegel WH (1997) Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol Endocrinol Metab 273: E981-E988.
26. Noguchi Y, Young JD, Aleman JO, Hansen ME, Kelleher JK, and Stephanopoulos G (2009) Effect of anaplerotic fluxes and amino acid availability on hepatic lipoapoptosis. J Biol Chem 284:33425-33436.
27. Raun K, von Voss P, Gotfredsen CF, Golozoubova V, Rolin B, and Knudsen LB (2007) Liraglutide, a long-acting glucagon-like peptide-1 analog, reduces body weight and food intake in obese candy-fed rats, whereas a dipeptidyl peptidase-IV inhibitor, vildagliptin, does not. Diabetes 56:8-15.
28. Redondo A, Trigo MV, Acitores A, Valverde I, and Villanueva- Peñacarrillo ML (2003) Cell signalling of the GLP-1 action in rat liver. Mol Cell Endocrinol 204:43-50. (Pubitemid 36871551)
29. Reed WD, Baab PJ, Hawkins RL, and Ozand PT (1984) The effects of insulin and glucagon on ketone-body turnover. Biochem J 221:439-444. (Pubitemid 14052338)
30. Unger RH and Orci L (1975) The essential role of glucagon in the pathogenesis of diabetes mellitus. Lancet 1:14-16.
31. Villanueva-Peñacarrillo ML, Alcántara AI, Clemente F, Delgado E, and Valverde I (1994) Potent glycogenic effect of GLP-1(7-36)amide in rat skeletal muscle. Diabetologia 37:1163-1166.
32. Wahl DR, Petersen B, Warner R, Richardson BC, Glick GD, and Opipari AW (2010) Characterization of the metabolic phenotype of chronically activated lymphocytes. Lupus 19:1492-1501.
33. Wang Y, Perfetti R, Greig NH, Holloway HW, DeOre KA, Montrose-Rafizadeh C, Elahi D, and Egan JM (1997) Glucagon-like peptide-1 can reverse the age-related decline in glucose tolerance in rats. J Clin Invest 99:2883-2889. (Pubitemid 27278664)
34. Wettergren A, Schjoldager B, Mortensen PE, Myhre J, Christiansen J, and Holst JJ (1993) Truncated GLP-1 (proglucagon 78-107-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 38:665-673. (Pubitemid 23121274)
35. Xu G, Stoffers DA, Habener JF, and Bonner-Weir S (1999) Exendin-4 stimulates both β-cell replication and neogenesis, resulting in increased β-cell mass and improved glucose tolerance in diabetic rats. Diabetes 48:2270-2276. (Pubitemid 30395416)
36. Xu J, Lloyd DJ, Hale C, Stanislaus S, Chen M, Sivits G, Vonderfecht S, Hecht R, Li YS, Lindberg RA, et al. (2009) Fibroblast growth factor 21 reverses hepatic steatosis, increases energy expenditure, and improves insulin sensitivity in diet-induced obese mice. Diabetes 58:250-259.
37. Yan H, Gu W, Yang J, Bi V, Shen Y, Lee E, Winters KA, Komorowski R, Zhang C, Patel JJ, et al. (2009) Fully human monoclonal antibodies antagonizing the glucagon receptor improve glucose homeostasis in mice and monkeys. J Pharmacol Exp Ther 329:102-111.
38. Zander M, Madsbad S, Madsen JL, and Holst JJ (2002) Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study. Lancet 359:824-830. (Pubitemid 34233752)